SMART TREATMENT FOR MALIGNANT PLEURAL MESOTHELIOMA

B.C. JOHN CHO MD, PhD, FRCPC
RADIATION ONCOLOGIST
ASSISTANT PROFESSOR, UNIVERSITY OF TORONTO, DEPARTMENT OF RADIATION ONCOLOGY (UTDRO)

HOW DO YOU MANAGE A RARE, COMPLEX CANCER THAT IS DIFFICULT TO DIAGNOSE? This is the question that Drs. John Cho and Marc de Perrot have attempted to answer using a multidisciplinary, collaborative approach and the SURGERY FOR MESOTHELIOMA AFTER RADIATION THERAPY or “SMART” treatment program at the Princess Margaret Cancer Centre. The SMART program aims to optimize treatment and prolong life for patients with malignant pleural mesothelioma (MPM), a rare thoracic cancer.

MPM is most commonly caused by occupational or environmental exposure to asbestos and affects the lining of the lungs (pleura). Symptoms are often non-specific and include progressive shortness of breath, cough, and chest wall pain. The diagnosis is challenging; patients typically undergo a series of tests and referrals, which may delay treatment.

In addition, the aggressive nature of MPM necessitates intensive treatment, which invariably increases the side effects and complications that patients experience. Due to these diagnostic and treatment challenges, the prognosis for patients with MPM remains poor, with a median survival of 12 months after diagnosis and rare long-term survival. Consequently, the management of MPM requires novel treatment options, multidisciplinary collaboration, and efficient coordination between medical specialties.

CONTINUED ON PAGE 2.

“I won the lottery, I survived. Somebody up there is looking over me, but boy did I ever have a lot of help down here. I can’t say enough about The Princess Margaret.”

—EDWARD EWING
The SMART treatment program includes radiation therapy (RT) prior to surgery. Although about half (52%) of patients experienced severe surgical complications with this aggressive approach, SMART is associated with a doubling of historical three-year overall survival, from 32% to 72%, and most surgical complications eventually resolve. For patients like Edward Ewing, a retired industrial worker, volunteer fire-fighter, and construction millwright, SMART has provided a “second chance at life”.

EDWARD EWING has come a long way since his MPM diagnosis in November 2010, when he was given 18 months to live, whether or not he had chemotherapy. Fortunately, he became the eleventh patient to benefit from the SMART program. Under the supervision of Dr. Cho, Edward Ewing was treated with RT daily for five days. On day seven, Dr. de Perrot removed his left lung and several back ribs; Edward was up and walking the next day!

In addition to innovative treatment approaches, multidisciplinary collaboration is integral to handling clinically complex cases such as Mr. Ewing’s and is essential for the optimal delivery of programs like SMART. Being cognizant of this, a new Mesothelioma Clinic, with all three oncologic disciplines (Thoracic Surgery, Radiation Oncology, and Medical Oncology) is located in the same physical space, facilitating faster referrals and multidisciplinary care. By concentrating the necessary clinical and research expertise into one clinic, the Princess Margaret Cancer Centre is able to provide more complete and specialized quality care for our MPM patients. Patients like Mr. Ewing, who benefited from SMART, experience shorter treatment, fewer complications, and faster recovery, which improves quality of life.
Clinical Trials Highlights

MESOTHELIOMA CANCER TRIALS AT RMP

B.C. JOHN CHO, MD, PhD, FRCPC

MARC DE PERROT, MD, MSc
ASSOCIATE PROFESSOR OF SURGERY, UNIVERSITY OF TORONTO, DIVISION OF THORACIC SURGERY, TORONTO GENERAL HOSPITAL

Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers

Pls – Demetris Patsios and Marc de Perrot

There is no currently accepted, non-invasive tool for the early diagnosis of mesothelioma or lung cancer in asbestos-exposed subjects. This study aims to develop low-dose computed tomography (CT) as a tool to serially image pleural plaques, quantify their individual and overall volume, compute the growth rate with time, and identify the presence of mesothelioma before symptoms occur. Results may prevent delays in treatment start times, thereby improving prognosis.

Eligible Patients: Ontario patients with prior asbestos exposure (at least 20 years ago) and/or documented pleural plaques (chest x-ray evidence).

ClinicalTrials.gov Identifier: NCT00188890

Short Neoadjuvant Hemithoracic IMRT for MPM: The SMART (Surgery for Mesothelioma After RT) Study

Pl - John Cho

Tumour spread outside the chest cavity may result in distant metastatic disease, a major cause of death among patients with MPM. This interventional study evaluates whether giving patients a short, intense course of chest radiation prior to surgery will sterilize tumour cells, thus avoiding or reducing spread to the areas outside of the chest cavity. The results of this study may reduce the incidence of distant metastatic disease in this patient population, ultimately improving survival.

Eligible Patients: Patients who have been diagnosed with early stage resectable MPM.

ClinicalTrials.gov Identifier: NCT00797719

DID YOU KNOW?

NEW RECRUITS TO THE RADIATION MEDICINE PROGRAM

THE RMP AT THE PRINCESS MARGARET CANCER CENTRE IS COMPOSED OF AN INTERNATIONAL, INTERDISCIPLINARY TEAM that is committed to providing exemplary care to our patients. The RMP has recently welcomed three radiation oncologists who bring experience and expertise in several aspects of radiation oncology.

DR. DAVID SHULTZ completed his MD/PhD at Case Western Reserve University in Ohio in 2009. He brings experience from Stanford University where he completed his postgraduate training in Radiation Oncology (RO) and worked as an instructor prior to joining the RMP in August 2015. Dr. Shultz is a member of the Central Nervous System (CNS) and Sarcoma site groups.

DR. JENNIFER CROKE completed her MD at Memorial University in Newfoundland in 2008 and her RO residency at the University of Ottawa in 2013. She completed a one-year Clinical Research Fellowship at the Princess Margaret, specializing in Gynecologic Oncology and MR-guided brachytherapy. She worked as a Radiation Oncologist in Newfoundland before returning to the Princess Margaret in September 2015. Dr. Croke is a member of the Gynecological (GYN) and Breast site groups.

DR. ALEJANDRO BERLIN completed his MD at Pontificia Universidad Católica de Chile in Santiago, Chile, in 2007 and his RO residency at the Universidad del Desarrollo in Chile. He worked for two years as a Radiation Oncologist in Chile and completed a two-year Research Fellowship at the Princess Margaret while obtaining a MSc degree from the Institute for Medical Sciences (IMS) at the University of Toronto. Dr Berlin is a member of the Genitourinary (GU) and CNS site groups.
HOW TO FIND US FOR YOUR REFERRALS
We offer three ways to facilitate your requests for consultation:

1. Site Group Coordinators
Site group coordinators serve as a liaison for referring physicians, radiation oncologists and the Princess Margaret Patient Referral Centre.

2. Princess Margaret New Patient Referral Centre
Tel: 416.946.4575
Fax: 416.946.2900

3. Direct to Specific Radiation Oncologists
Referrals to specific radiation oncologists should be directed to site group coordinators.

Palliative Radiation Oncology Program (PROP)
Direct palliative radiation referral patients to our PROP coordinator. Within 24 hours, she will contact you with an appointment. Patients will be seen within a few days. PROPRefferrals@rmp.uhn.ca

Melanie Robson
Coordinator
Tel: 416.946.2901
Fax: 416.946.4657
melanie.robson@rmp.uhn.ca

Dr. Laura Dawson
Leader
Tel: 416.946.2127
laura.dawson@rmp.uhn.ca

Referrals to specific radiation oncologists should be directed to site group coordinators.

CNS
Coordinator Chantel Credo
Tel: 416.946.2130
Fax: 416.946.4657
chantel.credo@rmp.uhn.ca

Dr. Normand Laperriere
Leader
Tel: 416.946.2127
normand.laperriere@rmp.uhn.ca

ENDOCRINE
Coordinator Chantel Credo
Tel: 416.946.2902
Fax: 416.946.4657
chantel.credo@rmp.uhn.ca

Dr. James Brierley
Leader
Tel: 416.946.2124
james.brierley@rmp.uhn.ca

GASTROINTESTINAL
Coordinator Anila Samji
Tel: 416.946.4501 x3639
Fax: 416.946.4657
anila.samji@rmp.uhn.ca

Dr. Anne Koch
Leader
Tel: 416.946.2122
anne.koch@rmp.uhn.ca

GYNAECOLOGICAL
Coordinator Anila Samji
Tel: 416.946.4501 x3639
Fax: 416.946.4657
anila.samji@rmp.uhn.ca

Dr. Michael Milosevic
Leader
Tel: 416.946.2122
michael.milosevic@rmp.uhn.ca

GENITOURINARY
Coordinator Anila Samji
Tel: 416.946.4501 x3639
Fax: 416.946.4657
anila.samji@rmp.uhn.ca

Dr. Charles Catton
Leader
Tel: 416.946.2983
charles.catton@rmp.uhn.ca

HEAD AND NECK
Coordinator Ellen Hoffman
Tel: 416.946.2130
Fax: 416.946.4657
ellen.hoffman@rmp.uhn.ca

Dr. John Waldron
Leader
Tel: 416.946.6522
john.waldron@rmp.uhn.ca

LYMPHOMA
Coordinator Chantel Credo
Tel: 416.946.2902
Fax: 416.946.4657
chantel.credo@rmp.uhn.ca

Dr. Richard Tsang
Leader
Tel: 416.946.6513
richard.tsang@rmp.uhn.ca

MULTI-DISCIPLINARY BRAIN METS CLINIC
Coordinator Sarin Ekizian
Tel: 416.946.2130
Fax: 416.946.4657
brainmetsclinic@rmp.uhn.ca

Dr. David Shultz
Leader
Tel: 416.946.6513
david.shultz@rmp.uhn.ca

PEDIATRICS
Coordinator Chantel Credo
Tel: 416.946.2902
Fax: 416.946.4657
chantel.credo@rmp.uhn.ca

Dr. David Hodgson
Leader
Tel: 416.946.2121
david.hodgson@rmp.uhn.ca

QPCR
 Coordinator Richard Tsang
 Tel: 416.946.6513
 Fax: 416.946.4657
 richard.tsang@rmp.uhn.ca

Dr. Daniel Martin
Leader
Tel: 416.946.2121
daniel.martin@rmp.uhn.ca

SARCOMA
Coordinator Melanie Robson
Tel: 416.946.2901
Fax: 416.946.4657
melanie.robson@rmp.uhn.ca

Dr. Brian O’ Sullivan
Leader
Tel: 416.946.2122
brian.osullivan@rmp.uhn.ca

SKIN
Coordinator Melanie Robson
Tel: 416.946.2901
Fax: 416.946.4657
melanie.robson@rmp.uhn.ca

Dr. Alex Sun
Leader
Tel: 416.946.2126
alex.sun@rmp.uhn.ca

ConneXions can be found online at www.radiationatpm.com. To comment, suggest future topics or to request an electronic version of ConneXions, please email us at connexions@rmp.uhn.ca.